Kolon TissueGene, Inc. (KOSDAQ: A950160)
Health Care · Biotechnology · US
₩16,030.00
-0.62% today · -64.4% 1Y
Kolon TissueGene, Inc. (KOSDAQ: A950160) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.01B.
Over the last twelve months the share price has lost 64.4%, trading between 11.47K and 149.00K.
Tweenvest scores Kolon TissueGene, Inc. across four factors: quality 38/100, value 32/100, growth 64/100. Its strongest factor is growth.
A950160 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.01B
- Revenue (TTM)
- $3.10M
- P/E
- —
- EPS
- -2,163.19
- Dividend yield
- —
- Beta (5Y)
- -0.33
- 52-week high
- ₩149,000.00
- 52-week low
- ₩11,470.00
- Avg volume (3M)
- —
- Shares outstanding
- 84.97M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MannKind CorporationNasdaqGM: MNKD | $1.06B | $3.29 | -13.42% |
| CStone PharmaceuticalsSEHK: 2616 | $1.03B | HK$5.09 | -9.99% |
| MeiraGTx Holdings plcNasdaqGS: MGTX | $1.03B | $10.69 | -0.93% |
| Immatics N.V.NasdaqCM: IMTX | $1.02B | $7.43 | -2.11% |
| Aktis Oncology, Inc.NasdaqGS: AKTS | $1.01B | $18.15 | +2.31% |
| Adlai Nortye Group Ltd.NasdaqGM: ANL | $1.01B | $15.62 | +3.51% |
| Cullinan Therapeutics, Inc.NasdaqGS: CGEM | $999.43M | $15.53 | +0.45% |
| Philogen S.p.A.BIT: PHIL | $991.45M | €22.00 | +0.69% |
Figures last refreshed Oct 11, 2026.